The progression-free survival (PFS) benefit observed with olaparib maintenance persists after treatment completion in patients with advanced ovarian cancer, according to research published in The Lancet Oncology. Five-year follow-up data from the phase 3 SOLO1 trial showed a sustained PFS benefit with 2 years of olaparib maintenance, compared with placebo, in patients with ovarian cancer. “To […]
According to HealthDay (10/27), “a new study reports that the COVID vaccines are producing little to no protection for some” patients with cancer. Researchers found that “nearly 3 out of 5 blood cancer patients failed to mount an immune response against COVID after receiving a full two-dose course of the Pfizer vaccine.” Individuals “with solid tumors also […]
Cancer Therapy Advisor (10/19, Lawrence) reported, “Changes in weight or body mass index (BMI) around the time of endometrial cancer diagnosis are associated with reduced survival, according to a study published in JNCI: Journal of the National Cancer Institute.” The study “showed that patients with a 5% or greater gain or loss in weight or BMI from 1 […]
Medscape (10/13, Stern, Subscription Publication) reported, “The US Food and Drug Administration (FDA) has approved the checkpoint inhibitor pembrolizumab…alongside standard chemotherapy — with or without bevacizumab — as first-line therapy for patients with persistent, recurrent, or metastatic PD-L1-expressing cervical cancer.” The agency “also announced the regular approval of pembrolizumab alone for patients with recurrent or metastatic […]
Newsweek (9/28, Sulleyman) reported on the efforts of Kari Neumayer to raise “awareness of ovarian cancer and how difficult it can be to detect, having been diagnosed with the illness by a dermatologist who removed a small growth from her navel.” Writing on HuffPost about her experience, Neumayer “said the growth inside her navel was, at […]
Cancer Network (9/14, Pelosci) reported, “Patients with gynecologic cancer who were carriers for a BRCA1/2 pathogenic variant and received risk-reducing salpingectomy (RRS) experienced improved menopause-related quality of life compared with those who received risk-reducing salpingo-oophorectomy (RRSO), regardless of treatment with hormone replacement therapy, according to findings from a study.” The research was published in JAMA Oncology. […]
Health IT Analytics (9/13, McNemar) reported a predictive model published in Cancer Epidemiology Biomarkers & Prevention “estimated that cervical cancer could be virtually eliminated in the United States by 2030 in communities with low poverty rates, but not until 2044 in communities with high poverty rates.” With HPV vaccines about “90 percent effective at preventing HPV-related cancers, vaccination […]
Cancer Therapy Advisor (8/16, Primeau) reported, “Researchers estimate that, over the next 15 years, the incidence of cervical cancer will remain stable or decrease in 19 countries, and cervical cancer mortality will remain stable or decrease in 26 countries.” The findings were published in Cancer. […]
Cancer Network (8/4, Pelosci) reported, “The identification of social needs and accompanying solutions could result in more actionable health care disparities and impact outcomes for women with gynecologic cancer, according to a study published in CANCER.” According to the study findings, “65.2% of women with a gynecologic malignancy had at least 1 unmet social need, with 37.8% of patients […]
Chemotherapy was not associated with increased risks of SARS-CoV-2 infection or COVID-19-related death in patients with breast cancer in a single-center study. The study results were presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting by Nibash Budhathoki, MBBS, of the NYU Long Island School of Medicine in Mineola, New York. Dr. […]